Roche dumps 4 eye, CNS and cancer drugs in Q4 clear-out

Roche logo

Swiss major Roche announced its financials today, and buried within its pipeline updates the company announced it was dumping a host of early- and late-stage candidates.

In phase 3 it has removed lampalizumab (RG7417), which last fall flopped two tests: Chroma and Spectri, which were assessing the drug in geographic atrophy (GA) due to age-related macular degeneration (AMD), and secondary to AMD.

Jefferies had tipped this drug to top out at $2 billion a year, but it has now been relegated to the Roche dustbin.


Lipid-based Formulations for Early Stage Clinical Trials

Liquid-filled capsule technology has a proven record for addressing complex API formulation challenges, but also offers a simple and effective pathway to the clinic. Register now to learn more about lipid-based formulations.

RELATED: Phase 3 fail puts Roche blockbuster-to-be on the critical list

Further back in phase 1 it’s also canning work on two cancer drugs: RG7986, an antibody drug conjugate for refractory B-cell non-Hodgkin’s lymphoma, and RG6047, which was being tested in metastatic estrogen receptor-positive, HER2-negative breast cancer.

The B-cell med had in fact been developed via Seattle Genetics' ADC tech. RG7604, meanwhile, is a small molecule PI3 kinase inhibitor.

And finally, it’s also curtains for RG7203, a small molecule inhibitor of phosphodiesterase 10A (PDE10A) for the treatment of schizophrenia.

RELATED: Roche dumps lead asset from its $725M Seragon buy


Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Invitae aims to expand its genetic counseling reach through the $50 million acquisition of Clear Genetics, developers of digital chatbot software.